An AI healthcare company claims that its software can more accurately determine the extent of prostate cancer compared to traditional methods used by doctors.
A recent study revealed that the pill version of Novo Nordisk’s drug Ozempic can reduce the risk of heart attacks and strokes, according to new research findings.
Avenda Health conducted a study last month involving ten doctors who evaluated 50 prostate cancer cases each. The company’s Unfold AI software achieved an accuracy rate of 84.7% in detecting cancer, whereas the physicians’ manual assessments ranged between 67.2% and 75.9%.
This study, conducted in collaboration with UCLA Health and published in the Journal of Urology, also indicated that utilizing AI for cancer contouring resulted in size predictions that were 45 times more accurate and consistent compared to assessments made without AI.
Shyam Natarajan, assistant adjunct professor of urology, surgery, and bioengineering at UCLA and senior author of the study, stated that the incorporation of AI assistance improved both accuracy and consistency among doctors, leading to a higher alignment in their assessments.
Typically, doctors rely on MRIs to gauge tumor sizes. However, as explained by Dr. Wayne Brisbane, an assistant professor of urology at UCLA’s David Geffen School of Medicine, certain tumors may not be visible on MRIs. AI technology can offer assistance in those cases.
“Using AI in cancer treatment could enhance personalized care for patients, tailoring treatments to their specific needs and improving the effectiveness of disease management,” Brisbane emphasized. He added that AI has the potential to “surpass human capabilities.”
Avenda Health’s CEO, Dr. Shyam Natarajan, expressed that it is “empowering for physicians to see this kind of innovation validated through studies and acknowledged by the AMA.”
According to the American Cancer Society, around 1 in 8 men in the U.S. will receive a prostate cancer diagnosis during their lifetime, and 1 in 44 will succumb to the disease.
This year, it is projected that there will be 299,010 new cases of prostate cancer in the United States, with an estimated 35,250 deaths attributed to the disease.